Orexigen Therapeutics

Orexigen’s commitment to patients is reflected in all that we do: we are a company driven by the knowledge that our work is important and the desire to make a difference.

Orexigen offers prospective employees exciting challenges, unique opportunities for career growth, and a fast-paced environment that emphasizes innovation and achievement.

Company Growth (employees)
San Diego, US
Size (employees)
67 (est)
Orexigen Therapeutics was founded in 2002 and is headquartered in San Diego, US

Orexigen Therapeutics Office Locations

Orexigen Therapeutics has an office in San Diego
San Diego, US (HQ)
200 3344 N Torrey Pines Ct

Orexigen Therapeutics Data and Metrics

Orexigen Therapeutics Financial Metrics

Orexigen Therapeutics's revenue was reported to be $24.5 m in FY, 2015 which is a 56% decrease from the previous period.
Numbers are in $, USD

Revenue (FY, 2015)

24.5 m

Revenue growth (FY, 2014 - FY, 2015), %


Net income (FY, 2015)

(68.7 m)

EBIT (FY, 2015)

(60.1 m)

Market capitalization (26-May-2017)

45.2 m

Closing share price (26-May-2017)


Cash (31-Dec-2015)

155.4 m
Orexigen Therapeutics's current market capitalization is $45.2 m.
Numbers are in $, USDFY, 2013FY, 2014FY, 2015


3.4 m55.5 m24.5 m

Revenue growth, %


Operating expense total

80.6 m86.1 m84.5 m


(77.2 m)(30.5 m)(60.1 m)

EBIT margin, %


Interest expense

538 k7.1 m7.4 m

Interest income

65 k88 k227 k

Pre tax profit

(67.3 m)

Income tax expense

(1.4 m)

Net Income

(77.7 m)(37.5 m)(68.7 m)
Numbers are in $, USDFY, 2013FY, 2014FY, 2015


98.1 m104.2 m155.4 m

Accounts Receivable

2.6 m6.8 m


1.3 m1.5 m2.3 m

Current Assets

178.3 m211.3 m233.9 m


630 k857 k1.3 m

Total Assets

180.1 m213 m236.6 m

Accounts Payable

4.8 m4.2 m6.5 m

Current Liabilities

22.9 m29.7 m32.2 m

Additional Paid-in Capital

556.2 m574.2 m653.7 m

Retained Earnings

(514.5 m)(552 m)(620.7 m)

Total Equity

41.9 m22.3 m33.4 m

Financial Leverage

4.3 x9.5 x7.1 x
Numbers are in $, USDFY, 2013FY, 2014FY, 2015

Net Income

(77.7 m)(37.5 m)(68.7 m)

Depreciation and Amortization

94 k139 k223 k

Accounts Receivable

(2.5 m)(4.3 m)


205 k(175 k)(781 k)

Accounts Payable

(2.3 m)2.1 m1 m

Cash From Operating Activities

(70.8 m)6.1 m51.2 m

Purchases of PP&E

(640 k)(246 k)(538 k)

Cash From Investing Activities

(21.3 m)(23.4 m)41.4 m

Cash From Financing Activities

111.9 m2.7 m64.3 m

Interest Paid

3.1 m3.2 m

Income Taxes Paid

28 k
Numbers are in $, USDY, 2015


520.4 k

Financial Leverage

7.1 x

Orexigen Therapeutics Market Value History

Orexigen Therapeutics Company Life and Culture

You may also be interested in